Anna D. Garrett, PharmD, BCPS, CPP
Published Online: Thursday, June 1, 2006

A recent study of the safety and efficacy of clopidogrel (Plavix; 75 mg per day) plus aspirin (75-162 mg per day), compared with aspirin alone, resulted in findings that suggested no benefits and possible harm from the combination of the 2 drugs. The study included 15,603 patients with either clinically evident cardiovascular disease (CVD) or multiple risk factors for CVD. After a median of 28 months of follow-up, the primary efficacy end point—a composite of myocardial infarction (MI), stroke, or death from cardiovascular causes—occurred in patients with established CVD at rates of 6.8% in the clopidogrel group and 7.3% in the placebo group. In patients with risk factors but no evidence of CVD, events occurred at rates of 6.6% in the clopidogrel group versus 5.5% in the placebo group. Although this finding was not statistically significant, the rates of death between the 2 groups did reach statistically significant levels. Severe bleeding risks were elevated in the combination group (1.7% vs 1.3%), as were the risks of moderate bleeding (2.1% vs 1.3%).

The American Heart Association has issued a statement specifying those patients that may benefit from the use of clopidogrel. They include some patients who have had an MI; patients who have had angioplasty for unstable angina or heart attack; patients who have received either a bare-metal or drug-eluting stent; patients with peripheral artery disease; and patients who have had a transient ischemic attack or other stroke.

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues